Clinical Trial Update: CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial investigating a CD19/CD22-targeted CAR-T therapy for B-cell acute lymphoblastic leukemia (B-ALL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CAR-T) (CD19/CD22-targeted CAR-T)

Snippet

Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Conditions: Leukemia, B-cell | Phase 1, Phase 2 | Status: UNKNOWN